Nishkantha Arulkumaran

Clinical review: Goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups

Maurizio Cecconi, Carlos Corredor, Nishkantha Arulkumaran et al. · Critical Care · 2012 · 341 citations · Full text

Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single-seropositive patients

Stephen P. McAdoo, Anisha Tanna, Zdenka Hrušková et al. · Kidney International · 2017 · 224 citations · Full text

Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study

Nishkantha Arulkumaran, N. Periselneris, G. Gaskin et al. · Lara D. Veeken · 2011 · 135 citations · Full text

Is the inflammasome a potential therapeutic target in renal disease?

Clare M. Turner, Nishkantha Arulkumaran, Mervyn Singer et al. · BMC Nephrology · 2014 · 86 citations · Full text

Use of non-invasive ventilation for patients with COVID-19: a cause for concern?

Nishkantha Arulkumaran, David Brealey, David Howell et al. · The Lancet Respiratory Medicine · 2020 · 86 citations · Full text